172 related articles for article (PubMed ID: 31497488)
1. The clinical profiles of female patients with Fabry disease in Latin America: A Fabry Registry analysis of natural history data from 169 patients based on enzyme replacement therapy status.
Martins AM; Cabrera G; Molt F; Suárez-Obando F; Valdés RA; Varas C; Yang M; Politei JM
JIMD Rep; 2019 Sep; 49(1):107-117. PubMed ID: 31497488
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: An analysis from the Fabry Registry.
Hopkin RJ; Cabrera GH; Jefferies JL; Yang M; Ponce E; Brand E; Feldt-Rasmussen U; Germain DP; Guffon N; Jovanovic A; Kantola I; Karaa A; Martins AM; Tøndel C; Wilcox WR; Yoo HW; Burlina AP; Mauer M
Mol Genet Metab; 2023 Feb; 138(2):106967. PubMed ID: 36709533
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry.
Hopkin RJ; Cabrera G; Charrow J; Lemay R; Martins AM; Mauer M; Ortiz A; Patel MR; Sims K; Waldek S; Warnock DG; Wilcox WR
Mol Genet Metab; 2016 Sep; 119(1-2):151-9. PubMed ID: 27510433
[TBL] [Abstract][Full Text] [Related]
4. The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts.
Germain DP; Elliott PM; Falissard B; Fomin VV; Hilz MJ; Jovanovic A; Kantola I; Linhart A; Mignani R; Namdar M; Nowak A; Oliveira JP; Pieroni M; Viana-Baptista M; Wanner C; Spada M
Mol Genet Metab Rep; 2019 Jun; 19():100454. PubMed ID: 30775256
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications.
Weidemann F; Niemann M; Störk S; Breunig F; Beer M; Sommer C; Herrmann S; Ertl G; Wanner C
J Intern Med; 2013 Oct; 274(4):331-41. PubMed ID: 23586858
[TBL] [Abstract][Full Text] [Related]
6. Enzyme replacement therapy for Fabry disease: a systematic review of available evidence.
Schaefer RM; Tylki-Szymańska A; Hilz MJ
Drugs; 2009 Nov; 69(16):2179-205. PubMed ID: 19852524
[TBL] [Abstract][Full Text] [Related]
7. Higher rate of rheumatic manifestations and delay in diagnosis in Brazilian Fabry disease patients.
Rosa Neto NS; Bento JCB; Pereira RMR
Adv Rheumatol; 2020 Jan; 60(1):7. PubMed ID: 31907047
[TBL] [Abstract][Full Text] [Related]
8. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.
Mignani R; Feriozzi S; Pisani A; Cioni A; Comotti C; Cossu M; Foschi A; Giudicissi A; Gotti E; Lozupone VA; Marchini F; Martinelli F; Bianco F; Panichi V; Procaccini DA; Ragazzoni E; Serra A; Soliani F; Spinelli L; Torti G; Veroux M; Cianciaruso B; Cagnoli L
Nephrol Dial Transplant; 2008 May; 23(5):1628-35. PubMed ID: 18057066
[TBL] [Abstract][Full Text] [Related]
9. Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain.
Rombach SM; Smid BE; Bouwman MG; Linthorst GE; Dijkgraaf MG; Hollak CE
Orphanet J Rare Dis; 2013 Mar; 8():47. PubMed ID: 23531228
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
Tsuboi K; Yamamoto H
BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
[TBL] [Abstract][Full Text] [Related]
11. Fabry Disease Patient-Reported Outcome (FD-PRO) demonstrates robust measurement properties for assessing symptom severity in Fabry disease.
Hamed A; DasMahapatra P; Lyn N; Gwaltney C; Iaconangelo C; Serrano D; Modur V; Politei J
Mol Genet Metab Rep; 2021 Dec; 29():100824. PubMed ID: 34900595
[TBL] [Abstract][Full Text] [Related]
12. Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis.
Beck M; Hughes D; Kampmann C; Larroque S; Mehta A; Pintos-Morell G; Ramaswami U; West M; Wijatyk A; Giugliani R;
Mol Genet Metab Rep; 2015 Jun; 3():21-7. PubMed ID: 26937390
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of renal function in patients treated with migalastat for Fabry disease.
Bichet DG; Torra R; Wallace E; Hughes D; Giugliani R; Skuban N; Krusinska E; Feldt-Rasmussen U; Schiffmann R; Nicholls K
Mol Genet Metab Rep; 2021 Sep; 28():100786. PubMed ID: 34401344
[TBL] [Abstract][Full Text] [Related]
14. Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages.
Rombach SM; Smid BE; Linthorst GE; Dijkgraaf MG; Hollak CE
J Inherit Metab Dis; 2014 May; 37(3):341-52. PubMed ID: 24492980
[TBL] [Abstract][Full Text] [Related]
15. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.
Hughes DA; Nicholls K; Shankar SP; Sunder-Plassmann G; Koeller D; Nedd K; Vockley G; Hamazaki T; Lachmann R; Ohashi T; Olivotto I; Sakai N; Deegan P; Dimmock D; Eyskens F; Germain DP; Goker-Alpan O; Hachulla E; Jovanovic A; Lourenco CM; Narita I; Thomas M; Wilcox WR; Bichet DG; Schiffmann R; Ludington E; Viereck C; Kirk J; Yu J; Johnson F; Boudes P; Benjamin ER; Lockhart DJ; Barlow C; Skuban N; Castelli JP; Barth J; Feldt-Rasmussen U
J Med Genet; 2017 Apr; 54(4):288-296. PubMed ID: 27834756
[TBL] [Abstract][Full Text] [Related]
16. Fabry in the older patient: Clinical consequences and possibilities for treatment.
Lidove O; Barbey F; Niu DM; Brand E; Nicholls K; Bizjajeva S; Hughes DA
Mol Genet Metab; 2016 Aug; 118(4):319-25. PubMed ID: 27221354
[TBL] [Abstract][Full Text] [Related]
17. Fabry Disease and the Effectiveness of Enzyme Replacement Therapy (ERT) in Left Ventricular Hypertrophy (LVH) Improvement: A Review and Meta-Analysis.
Lee CL; Lin SP; Niu DM; Lin HY
Int J Med Sci; 2022; 19(1):126-131. PubMed ID: 34975306
[No Abstract] [Full Text] [Related]
18. Disease Progression Modeling to Evaluate the Effects of Enzyme Replacement Therapy on Kidney Function in Adult Patients with the Classic Phenotype of Fabry Disease.
Nowak A; Koch G; Huynh-Do U; Siegenthaler M; Marti HP; Pfister M
Kidney Blood Press Res; 2017; 42(1):1-15. PubMed ID: 28253518
[TBL] [Abstract][Full Text] [Related]
19. Clinical profile of women diagnosed with Fabry disease non receiving enzyme replacement therapy.
Barba-Romero MÁ; Serena J; Puig JM; Valverde C V; Climent V; Herrero JA; Huertas R; Torra R
Med Clin (Barc); 2019 Jul; 153(2):47-55. PubMed ID: 30658922
[TBL] [Abstract][Full Text] [Related]
20. Anderson-Fabry disease: a multiorgan disease.
Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]